Skip to content
HowShorted

Inhibikase Therapeutics, Inc. short interest in 2022

In 2022, Inhibikase Therapeutics, Inc.'s disclosed short interest ran from 0.76% of shares outstanding on 14 Jan 2022 to 0.75% on 30 Dec 2022, a change of -0.01 percentage points. The year's high was 0.78% on 31 Mar 2022 and its low 0.24% on 15 Aug 2022, averaging 0.55% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.72 days on 14 Apr 2022. Full history: Inhibikase Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Inhibikase Therapeutics, Inc. in 2022

2022 in figures

Start of year
0.76% (14 Jan 2022)
End of year
0.75% (30 Dec 2022)
Change
-0.01 pp
High
0.78% (31 Mar 2022)
Low
0.24% (15 Aug 2022)
Average
0.55%
Highest days to cover
2.72 (14 Apr 2022)
SEC filings marked
5

Every report in 2022

Inhibikase Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20220.76%1.00
31 Jan 20220.64%1.09
15 Feb 20220.50%1.99
28 Feb 20220.61%1.37
15 Mar 20220.76%1.59
31 Mar 20220.78%2.6510-K filed
14 Apr 20220.62%2.72
29 Apr 20220.41%1.09
13 May 20220.39%1.00
31 May 20220.67%1.0210-Q filed
15 Jun 20220.35%1.00
30 Jun 20220.38%1.42
15 Jul 20220.40%2.46
29 Jul 20220.31%1.77
15 Aug 20220.24%1.0010-Q filed
15 Nov 20220.78%1.0010-Q filed
30 Nov 20220.56%2.05results (8-K)
15 Dec 20220.54%2.45
30 Dec 20220.75%1.93

See also: Inhibikase Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.